Fortress Biotech, Inc. (FBIOP) FCF Margin (2015 - 2025)
Fortress Biotech (FBIOP) posted quarterly FCF Margin of 89.24% for Q4 2025, down 411.0% year-over-year from 28.7% in Q4 2024, and down 157.52% quarter-over-quarter from 34.65% in Q3 2025.
Fortress Biotech, Inc. (FBIOP) FCF Margin (2015 - 2025) Analysis & Trends
Fortress Biotech's FCF Margin history runs 11 years deep, the most recent figure standing at 89.24% for Q4 2025.
- In Q4 2025, FCF Margin fell 411.0% year-over-year to 89.24%; the TTM figure through Dec 2025 stood at 109.93% (up 2901.0% YoY), while the FY2025 annual figure was 107.41%, up 3163.0% from the prior year.
- FCF Margin for Q4 2025 stood at 89.24%, down from 34.65% in the prior quarter.
- The five-year high for FCF Margin was 87.96% in Q4 2022, with the low at 23266.45% in Q2 2021.
- The 5-year median for FCF Margin is 189.23% (2025), against an average of 3759.46%.
- The sharpest annual moves came in 2021 and 2022: FCF Margin plunged 2308655 bps in 2021, then soared 2303760 bps in 2022.
- Fortress Biotech's FCF Margin stood at 69.51% in 2021, then jumped by 227 bps to 87.96% in 2022, then plunged by 361 bps to 229.16% in 2023, then soared by 63 bps to 85.13% in 2024, then declined by 5 bps to 89.24% in 2025.
- Business Quant data shows FBIOP's FCF Margin at 89.24% in Q4 2025, 34.65% in Q3 2025, and 183.62% in Q2 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -89.24% |
| Sep 30, 2025 | -34.65% |
| Jun 30, 2025 | -183.62% |
| Mar 31, 2025 | -148.89% |
| Dec 31, 2024 | -85.13% |
| Sep 30, 2024 | -127.58% |
| Jun 30, 2024 | -155.97% |
| Mar 31, 2024 | -194.83% |
| Dec 31, 2023 | -229.16% |
| Sep 30, 2023 | -9,219.78% |
| Jun 30, 2023 | -18,200.55% |
| Mar 31, 2023 | -355.43% |
| Dec 31, 2022 | 87.96% |
| Sep 30, 2022 | -11,442.31% |
| Jun 30, 2022 | -228.85% |
| Mar 31, 2022 | -8,353.03% |
| Dec 31, 2021 | -69.51% |
| Sep 30, 2021 | -112.99% |
| Jun 30, 2021 | -23,266.45% |
| Mar 31, 2021 | -2,779.13% |